VolitionRx (NYSE:VNRX) Announces Earnings Results

VolitionRx (NYSE:VNRX) issued its quarterly earnings results on Monday. The company reported ($0.11) earnings per share (EPS) for the quarter, Zacks reports. The business had revenue of $0.24 million for the quarter, compared to analysts’ expectations of $0.50 million. VolitionRx had a negative net margin of 4,557.29% and a negative return on equity of 7,185.73%.

VolitionRx Price Performance

Shares of VNRX traded down $0.02 during mid-day trading on Wednesday, reaching $0.73. The stock had a trading volume of 193,804 shares, compared to its average volume of 184,596. The firm has a market cap of $57.05 million, a price-to-earnings ratio of -1.45 and a beta of 1.38. VolitionRx has a 12 month low of $0.55 and a 12 month high of $2.10. The business has a fifty day moving average of $1.00 and a 200 day moving average of $0.87. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.69 and a current ratio of 0.69.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $2.50 target price on shares of VolitionRx in a report on Wednesday.

Hedge Funds Weigh In On VolitionRx

An institutional investor recently raised its position in VolitionRx stock. Vanguard Group Inc. lifted its stake in VolitionRx Limited (NYSE:VNRX) by 4.2% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 542,444 shares of the company’s stock after buying an additional 22,046 shares during the quarter. Vanguard Group Inc. owned approximately 0.69% of VolitionRx worth $374,000 at the end of the most recent reporting period. 8.09% of the stock is currently owned by hedge funds and other institutional investors.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 worldwide. It offers Nu.Q Vet cancer screening blood test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer that detect cancer; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes.